A Phase II Evaluating Cabazitaxel in Patients With Brain Metastasis Secondary to Breast and Non-small Cell Lung Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2015
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Advanced breast cancer; Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CRANIAL
- 20 Sep 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-005194-32 )
- 23 Jul 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 01 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.